Clinical Trial Update: Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer [Phase 2]

View source ↗

Summary

This update reports on the trafficking of Indium-III-labeled cultured immune cells in patients with cancer receiving immunotherapy in a Phase 2 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasm | Phase 2 | Status: COMPLETED